In the pursuit of market outperformance, investors navigate the landscape of stock selection. The right picks can play a pivotal role in enhancing your wealth.
The price of Jazz Pharmaceuticals plc (NASDAQ: JAZZ) closed at $119.2 in the last session, up 1.30% from day before closing price of $117.67. In other words, the price has increased by $1.30 from its previous closing price. On the day, 0.89 million shares were traded. JAZZ stock price reached its highest trading level at $120.395 during the session, while it also had its lowest trading level at $117.6977.
Ratios:
We take a closer look at JAZZ’s different ratios to gain a better understanding of the stock. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 4.33 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 5.72. For the most recent quarter (mrq), Quick Ratio is recorded 1.37 and its Current Ratio is at 1.62. In the meantime, Its Debt-to-Equity ratio is 1.47 whereas as Long-Term Debt/Eq ratio is at 1.18.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Deutsche Bank on July 15, 2025, initiated with a Buy rating and assigned the stock a target price of $152.
On March 07, 2025, UBS Upgraded its rating to Buy which previously was Neutral and also upped its target price recommendation from $145 to $179.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Aug 08 ’25 when Winningham Rick E bought 3,731 shares for $112.00 per share.
Kennedy Patrick bought 3,731 shares of JAZZ for $417,872 on Aug 08 ’25. On Aug 08 ’25, another insider, ENRIGHT PATRICK G, who serves as the Director of the company, bought 3,731 shares for $112.00 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, JAZZ now has a Market Capitalization of 7230529024 and an Enterprise Value of 10900920320. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.77 while its Price-to-Book (P/B) ratio in mrq is 1.95. Its current Enterprise Value per Revenue stands at 2.667 whereas that against EBITDA is 6.82.
Stock Price History:
The Beta on a monthly basis for JAZZ is 0.24, which has changed by 0.042322516 over the last 52 weeks, in comparison to a change of 0.14064062 over the same period for the S&P500. Over the past 52 weeks, JAZZ has reached a high of $148.06, while it has fallen to a 52-week low of $95.49. The 50-Day Moving Average of the stock is 6.23%, while the 200-Day Moving Average is calculated to be 0.35%.
Shares Statistics:
According to the various share statistics, JAZZ traded on average about 767.75K shares per day over the past 3-months and 1040390 shares per day over the past 10 days. A total of 60.64M shares are outstanding, with a floating share count of 57.71M. Insiders hold about 4.86% of the company’s shares, while institutions hold 102.29% stake in the company. Shares short for JAZZ as of 1753920000 were 5483116 with a Short Ratio of 7.14, compared to 1751241600 on 5869994. Therefore, it implies a Short% of Shares Outstanding of 5483116 and a Short% of Float of 10.4499996.
Earnings Estimates
The performance of Jazz Pharmaceuticals plc (JAZZ) in the stock market is under the watchful eye of 17.0 analysts actively contributing to its current rating.The consensus estimate for the next quarter is $5.73, with high estimates of $6.17 and low estimates of $5.17.
Analysts are recommending an EPS of between $5.6 and $4.87 for the fiscal current year, implying an average EPS of $5.27. EPS for the following year is $21.55, with 17.0 analysts recommending between $25.45 and $16.72.
Revenue Estimates
According to 16 analysts, the current quarter’s revenue is expected to be $1.11B. It ranges from a high estimate of $1.13B to a low estimate of $1.07B. As of the current estimate, Jazz Pharmaceuticals plc’s year-ago sales were $1.05BFor the next quarter, 16 analysts are estimating revenue of $1.16B. There is a high estimate of $1.22B for the next quarter, whereas the lowest estimate is $1.13B.
A total of 18 analysts have provided revenue estimates for JAZZ’s current fiscal year. The highest revenue estimate was $4.3B, while the lowest revenue estimate was $4.16B, resulting in an average revenue estimate of $4.21B. In the same quarter a year ago, actual revenue was $4.07BBased on 18 analysts’ estimates, the company’s revenue will be $4.46B in the next fiscal year. The high estimate is $4.78B and the low estimate is $4.17B.
